Rise Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Rise Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-170	Closed	-$66.6K	–	1397
2025 Q3	$66.6K	Buy	170 +4	+2%	+$1.67K	0.02%	210
2025 Q2	$73.9K	Sell	166 -1	-0.6%	-$461	0.03%	191
2025 Q1	$81K	Buy	167 +14	+9%	+$6.52K	0.04%	169
2024 Q4	$61.6K	Sell	153 -5	-3%	-$2.32K	0.03%	195
2024 Q3	$73.5K	Buy	158 +2	+1%	+$961	0.04%	173
2024 Q2	$73.1K	Hold	156	–	–	0.04%	180
2024 Q1	$65.2K	Buy	156 +151	+3,020%	+$63.8K	0.03%	187
2023 Q4	$2.03K	Hold	5	–	–	﹤0.01%	466
2023 Q3	$1.74K	Hold	5	–	–	﹤0.01%	485
2023 Q2	$1.76K	Hold	5	–	–	﹤0.01%	531
2023 Q1	$1.57K	Hold	5	–	–	﹤0.01%	598
2022 Q4	$1.44K	Hold	5	–	–	﹤0.01%	610
2022 Q3	$1K	Hold	5	–	–	﹤0.01%	688
2022 Q2	$1K	Hold	5	–	–	﹤0.01%	686
2022 Q1	$1K	Buy	+5	New	+$1.19K	﹤0.01%	644

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Rise Advisors's VRTX Position: Q4 2025 in Review

Rise Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 170 shares — an estimated $66.6K sold.

Rise Advisors first reported a position in VRTX in Q1 2022 and held it in 15 quarters. The position peaked at $81K in Q1 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Rise Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 170 Vertex Pharmaceuticals shares in Q4 2025, an estimated $66.6K.
Rise Advisors first reported a position in Vertex Pharmaceuticals in Q1 2022 and held it in 15 quarters.
Rise Advisors's Vertex Pharmaceuticals position peaked at $81K in Q1 2025.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.